This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
BioMarin Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 5/6
BioMarin Pharmaceutical has been growing earnings at an average annual rate of 13.7%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 7.8% per year. BioMarin Pharmaceutical's return on equity is 3%, and it has net margins of 6.4%.
Belangrijke informatie
13.7%
Groei van de winst
13.6%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | -14.6% |
| Inkomstengroei | 7.8% |
| Rendement op eigen vermogen | 3.0% |
| Nettomarge | 6.4% |
| Volgende winstupdate | 22 Feb 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe BioMarin Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 23 | 2,311 | 147 | 908 | 0 |
| 30 Jun 23 | 2,235 | 100 | 901 | 0 |
| 31 Mar 23 | 2,173 | 72 | 880 | 0 |
| 31 Dec 22 | 2,096 | 142 | 854 | 0 |
| 30 Sep 22 | 2,008 | 84 | 826 | 0 |
| 30 Jun 22 | 1,912 | 54 | 792 | 0 |
| 31 Mar 22 | 1,880 | 39 | 780 | 0 |
| 31 Dec 21 | 1,846 | -64 | 759 | 0 |
| 30 Sep 21 | 1,849 | 16 | 737 | 0 |
| 30 Jun 21 | 1,917 | 837 | 733 | 0 |
| 31 Mar 21 | 1,844 | 795 | 725 | 0 |
| 31 Dec 20 | 1,860 | 854 | 738 | 0 |
| 30 Sep 20 | 1,863 | 852 | 730 | 0 |
| 30 Jun 20 | 1,847 | 122 | 721 | 0 |
| 31 Mar 20 | 1,805 | 114 | 706 | 0 |
| 31 Dec 19 | 1,704 | -24 | 681 | 0 |
| 30 Sep 19 | 1,603 | -43 | 657 | 0 |
| 30 Jun 19 | 1,533 | -110 | 636 | 0 |
| 31 Mar 19 | 1,519 | -90 | 628 | 0 |
| 31 Dec 18 | 1,491 | -77 | 604 | 0 |
| 30 Sep 18 | 1,496 | -125 | 600 | 0 |
| 30 Jun 18 | 1,439 | -125 | 582 | 0 |
| 31 Mar 18 | 1,383 | -145 | 573 | 0 |
| 31 Dec 17 | 1,314 | -117 | 554 | 0 |
| 30 Sep 17 | 1,255 | -156 | 537 | 0 |
| 30 Jun 17 | 1,201 | -181 | 525 | 0 |
| 31 Mar 17 | 1,184 | -563 | 491 | 0 |
| 31 Dec 16 | 1,117 | -630 | 477 | 0 |
| 30 Sep 16 | 1,045 | -471 | 441 | 0 |
| 30 Jun 16 | 974 | -524 | 416 | 0 |
| 31 Mar 16 | 924 | -187 | 408 | 0 |
| 31 Dec 15 | 890 | -172 | 402 | 0 |
| 30 Sep 15 | 892 | -310 | 385 | 0 |
| 30 Jun 15 | 859 | -212 | 366 | 0 |
| 31 Mar 15 | 801 | -163 | 332 | 0 |
| 31 Dec 14 | 749 | -134 | 299 | 0 |
| 30 Sep 14 | 666 | -126 | 274 | 0 |
| 30 Jun 14 | 627 | -187 | 262 | 0 |
| 31 Mar 14 | 572 | -175 | 244 | 0 |
| 31 Dec 13 | 548 | -176 | 235 | 0 |
| 30 Sep 13 | 534 | -167 | 219 | 0 |
| 30 Jun 13 | 525 | -120 | 203 | 0 |
| 31 Mar 13 | 512 | -130 | 204 | 0 |
Kwaliteitswinsten: BM8 has high quality earnings.
Groeiende winstmarge: BM8's current net profit margins (6.4%) are higher than last year (4.2%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: BM8 has become profitable over the past 5 years, growing earnings by 13.7% per year.
Versnelling van de groei: BM8's earnings growth over the past year (75.2%) exceeds its 5-year average (13.7% per year).
Winst versus industrie: BM8 earnings growth over the past year (75.2%) exceeded the Biotechs industry -20.2%.
Rendement op eigen vermogen
Hoge ROE: BM8's Return on Equity (3%) is considered low.